Business Wire

Key Identity Verification Trends for 2025: Regula's Expert Insights

21.1.2025 14:30:00 CET | Business Wire | Press release

Share

Regula, a global developer of forensic devices and identity verification solutions, unveils its vision for the identity verification (IDV) industry in 2025. As new and persistent threats converge with evolving regulations and user expectations, they bring to life new requests for significant technological advancements in IDV.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250121753818/en/

Regula's experts share their insights into how identity verification will evolve in 2025 (Graphic: Regula)

Threats shaping the IDV landscape

The rise in identity fraud over the past two years has significantly impacted all industries, especially Finance, Banking, FinTech, and Crypto. With deepfakes threatening every second company around the world, businesses won’t be able to stand out without liveness checks, both for biometrics and documents. However, organizations can’t blindly rely on this method as-is. They will have to introduce signal source control viahardware-enabled solutions. With deepfakes being so deeply realistic now, humans often fail to distinguish between what is fake and what is real. That is why checking signal source integrity is crucial, as it helps ensure that no injection is done during the video session within the IDV process.

Also, businesses will further reinforce their biometric verification methods, such as facial recognition, fingerprint scanning, and voice identification, as they add additional defense.

Interestingly, traditional threats like fake IDs and synthetic fraud still account for the majority of identity fraud attempts. This highlights the need for businesses to balance preparing for sophisticated future attacks with addressing the more prevalent threats of today.

Regulations and user expectations: Growing demand and pressure

The IDV landscape is evolving due to stricter laws, rising user expectations, and new workforce demands. Governments are enforcing tighter age verification to protect minors and regulate restricted services. This will be driving further technologies like biometric age estimation.

Users seek fast, personalized IDV solutions, while businesses require flexible systems. So, the IDV industry will continue developing toward user-centric design, where convenience and personalization are prioritized.

Additionally, a new IDV user category is emerging: the workforce. In the era of remote and hybrid work, identity verification for employees is critical to prevent fraud, such as fake identities and ghost employees.

Technological shifts

The evolving challenges of fraud, compliance, and user demands are driving advancements in IDV technologies and the adoption of new digital identity documentslike the Digital Travel Credential (DTC), mobile driver’s licenses (mDLs), digital identity, etc.

To ensure more efficient fraud prevention, identity verification will extend beyond traditional document and biometric checks to include additional methods, such as direct validation against governments’ or issuing authorities’ databases. Also, IDV technologies will be more deeply integrated with other IT solutions deployed in organizations to create secure ecosystems.

Journey Time Orchestration (JTO) is gaining traction, offering a dynamic platform approach to managing identity tasks across the user journey by unifying biometrics, passwords, and third-party systems to balance security and convenience.

Last but not least, AI and ML technologies will be gaining momentum in identity verification. They have been used in IDV solutions for some time already, but their influence will become more tangible as AI-generated fraud evolves into a very significant threat to businesses worldwide.

“The identity verification industry is driven by the multiple forces of advanced threats, rising user demands, tightening regulation, and technological advancements. As we move into 2025, the challenge will be to create solutions that not only address sophisticated fraud but also prioritize user convenience and regulatory compliance,” said Ihar Kliashchou, Chief Technology Officer at Regula.

To get more insights on the trends that will shape IDV in the coming year, read our blog article.

About Regula

Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.

Learn more at www.regulaforensics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250121753818/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye